Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 3/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1422774 | 0.91 | MET (0.41) | IRAK4KDM5AMETMKNK1LRRK2 | |
| SCHEMBL16975513 | 0.89 | IRAK4 (0.41) | IRAK4KDM5AJAK1 | |
| SCHEMBL30426320 | 0.89 | IRAK4 (0.41) | IRAK4KDM5AJAK1 | |
| SCHEMBL15134755 | 0.89 | KDM5A (0.41) | KDM5ALRRK2 | |
| Hydrochloric Acid SCHEMBL16593449 | 0.89 | MET (0.42) | IRAK4KDM5AMETMKNK1LRRK2 | |
| Hydrochloric Acid SCHEMBL15875304 | 0.89 | MET (0.42) | IRAK4KDM5AMETMKNK1LRRK2 | |
| SCHEMBL17076755 | 0.86 | LRRK2 (0.42) | KDM5ALRRK2 | |
| SCHEMBL15244353 | 0.83 | ALOX15 (0.45) | KDM5AMET | |
| SCHEMBL1703399 | 0.81 | LRRK2 (0.40) | IRAK4KDM5AMETMKNK1LRRK2 | |
| SCHEMBL1703270 | 0.81 | LRRK2 (0.40) | IRAK4KDM5AMETMKNK1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019382-A1 | NOVEL INHIBITORS OF CYCLIN-DEPENDENT KINASES | ORIGENIS GMBH (DE) | 2025-01-16 | — | — | US | disclosed |
| EP-4436970-A1 | PYRAZOLOTRIAZINE DERIVATIVES USEFUL AS CDK9 INHIBITORS | Origenis GmbH (DE) | 2024-10-02 | — | — | EP | disclosed |
| CN-118284610-A | Pyrazolotriazine derivatives as CDK9 inhibitors | 原真股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| WO-2023094310-A1 | PYRAZOLOTRIAZINE DERIVATIVES USEFUL AS CDK9 INHIBITORS | ORIGENIS GMBH (DE) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023094310-A1 | PYRAZOLOTRIAZINE DERIVATIVES USEFUL AS CDK9 INHIBITORS | ORIGENIS GMBH (DE) | 2023-06-01 | — | — | WO | disclosed |
| EP-2821402-B1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2019-08-21 | — | — | EP | disclosed |
| US-20170152232-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2017-06-01 | — | — | US | disclosed |
| US-20170152232-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2017-06-01 | — | — | US | disclosed |
| US-9464077-B2 | Nitrogen-containing aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-10-11 | — | — | US | disclosed |
| US-9464077-B2 | Nitrogen-containing aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-10-11 | — | — | US | disclosed |
| EP-2821402-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2015-01-07 | — | — | EP | disclosed |
| US-20140142084-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20140142084-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) | 2014-05-22 | — | — | US | disclosed |
| WO-2013129369-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | アステラス製薬株式会社 (JP) | 2013-09-06 | — | — | WO | disclosed |
| WO-2012010704-A1 | NEW AMINOPYRAZOLOQUINAZOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142084-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | FGFR3, FGFR1, FGFR2 | IRAK4 1204/4885KDM5A 465/4885MET 59/4885 |
| US-20170152232-A1 | NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | FGFR3, FGFR1, FGFR2 | IRAK4 1167/4885KDM5A 411/4885MET 48/4885 |
| US-20250019382-A1 | NOVEL INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK9, CDK2, CDK19 | IRAK4 970/4885KDM5A 2687/4885MET 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.